FAP and neoplasm: The pretargeting strategy was subsequently tested in a pancreatic ductal adenocarcinoma patient-derived xenograft model, which better mimics tumor heterogeneity and stromal structure compared to U87MG xenografts, but exhibits significantly lower FAP expression.